Novel tumor vaccine gp96-Ig fusion heat shock protein in advanced non-small cell lung cancer (NSCLC) patients who have failed palliative chemotherapy and erlotinib

被引：0
|
作者：
Podack, E.
Raez, L. E.
Fisher, E.
Leibovitch, E.
Gomez, J. E.
Baldie, P.
Tolba, K. A.
Santos, E. S.
Walker, G.
机构：
[1] Univ Miami, Miami, FL USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Univ Miami, Sch Med, Miami, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18042
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Gastrointestinal hemorrhage in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib and celecoxib.
    Fidler, M. J.
    Argiris, A.
    Patel, J. D.
    Johnson, D. H.
    Sandler, A.
    Villaflor, V.
    Coon, J.
    Buckingham, L.
    Bonomi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 407S - 407S
  • [22] Toxicity and outcomes for patients with resected Non-Small cell lung cancer (NSCLC) who have received adjuvant chemotherapy in Bristol
    Ball, Jessica
    Ayre, Gareth
    Comins, Charles
    Dangoor, Adam
    Brooks, Helen
    Owadally, Waheeda
    LUNG CANCER, 2024, 190
  • [23] EVALUATION OF THE QUALITY OF LIFE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WHO FAILED TO FIRST LINE CHEMOTHERAPY IN TREATMENT WITH ERLOTINIB VS TAXANES
    Vargas, J.
    Gomez Rangel, J. D.
    Martinez-Barrera, L.
    Mendoza, D.
    Paladio, A.
    VALUE IN HEALTH, 2009, 12 (07) : A284 - A284
  • [24] Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy
    Chen, Yuh-Min
    Perng, Reury-Perng
    Shih, Jen-Fu
    Tsai, Chun-Ming
    Whang-Peng, Jacqueline
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (06) : 545 - 550
  • [25] Chemotherapy in elderly patients with advanced lung cancer - Part II: Treatment of non-small cell lung cancer (NSCLC)
    Honecker, F
    Wedding, U
    Bokemeyer, C
    ONKOLOGIE, 2004, 27 (06): : 583 - 588
  • [26] Population-based evaluation of second-line palliative chemotherapy (SCT) versus erlotinib (E) in advanced non-small cell lung cancer (NSCLC) patients (pts).
    Noonan, Krista
    Ho, Cheryl
    Sun, Sophie
    Melosky, Barbara L.
    Laskin, Janessa J.
    Murray, Nevin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [28] A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC)
    Lind, J. S.
    Dingemans, A. C.
    Groen, H. J.
    Smit, E. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] A phase II study of erlotinib followed by chemotherapy on progression in an unselected population of advanced non-small cell lung cancer (NSCLC) patients.
    Horn, Leora
    Li, Chung-I
    Pao, William
    Keedy, Vicki Leigh
    Johnson, David H.
    Carbone, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC)
    Lind, Joline S.
    Dingemans, Anne-Marie C.
    Groen, Harry J.
    Smit, Egbert F.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S412 - S413
12345